Casi Pharmaceuticals News and Activities

Casi Pharmaceuticals is a company listed under the stock ticker CASI (US).

Casi Pharmaceuticals has a direct presence in 2 countries.

They are in:

• Pharmaceuticals67%
• Biotechnology33%

View the org chart displaying its 43 main executives

Most searched biographies at Casi Pharmaceuticals

• David Cory, Chief Executive Officer
• Alexander Wu, Director
• Wei-Wu He, Director

Popular executive movements at Casi Pharmaceuticals

• Wei-Wu He who was Executive Chairman of the Board, becomes Director  (posted on November 20 2025).
• Barbara Krebs-Pohl has joined the company as Non Executive Board Member  (posted on October 27 2025).
• James Huang has joined the company as Director  (posted on September 26 2025).

Create your alert
to follow the executive moves at Casi Pharmaceuticals.

Casi Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Casi Pharmaceuticals

• CASI Pharmaceuticals Announces First Quarter 2024 Business and Financial Results-Press Releases-CASI
• CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results-Press Releases-CASI
• Press Releases-CASI
• CASI Pharmaceuticals Reports Development Relating To Its Disputes With Juventas-Press Releases-CASI
• CASI Pharmaceuticals | CASI Pharmaceuticals Announces First Quarter 2023 Financial Results
• CASI Pharmaceuticals | CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
• CASI Pharmaceuticals | CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022
• CASI Pharmaceuticals | CASI Pharmaceuticals Completes Redomiciliation Merger
• CASI Pharmaceuticals | CASI Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339 In Patients With Multiple Myeloma In China
• CASI Pharmaceuticals | CASI Pharmaceuticals’ Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration
• View more press releases Close

Social media about Casi Pharmaceuticals

• Casi Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Casi Pharmaceuticals on LinkedIn, X (Twitter) & YouTube